Loading...
Loading...
Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc.. Spoken Alpha tracks KLRA's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks KLRA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for KLRA.
curl https://api.spokenalpha.com/v1/companies/KLRA| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.13 | $2.11 | +48.2% | +8.9% | +6.9% |
| Q4 FY2026 | $2.92 | $2.08 | +40.4% | +1.0% | -0.6% |
| Q3 FY2026 | $3.35 | $2.22 | +51.1% | +8.5% | +7.4% |
| Q2 FY2026 | $3.21 | $2.14 | +49.8% | -0.3% | -0.4% |
| Q1 FY2025 | $2.96 | $2.14 | +38.2% | +3.9% | +2.5% |
| Q4 FY2025 | $3.17 | $2.21 | +43.6% | +2.9% | +0.3% |
| Q3 FY2025 | $3.24 | $2.19 | +48.0% | +1.8% | -0.9% |
| Q2 FY2025 | $3.35 | $2.37 | +41.5% | -1.9% | -4.0% |
| Q1 FY2024 | $3.28 | $2.36 | +38.8% | +5.7% | +7.4% |
| Q4 FY2024 | $3.64 | $2.43 | +49.9% | -1.6% | -4.6% |